MRD testing hits mainstream as natera scales signatera trials
The gist
Minimal residual disease (MRD) testing just went mainstream, as Natera’s Signatera powers pivotal trials and serial surveillance across cancer care.
What to know
- Natera and Genentech launched the 2,000-patient NAVIGATE Phase III trial in October 2026, using Signatera MRD results to trigger treatment decisions.
- MRD-guided care is now backed by robust clinical data—Natera’s tech appeared in 25 ESMO abstracts, with Myriad and others showing MRD detection can spot cancer recurrence up to four months earlier.
- Signatera is scaling fast, processing 249,000 clinical oncology units in Q1 alone, spanning more than 20 cancer indications and enabling routine three-month surveillance for survivors.
NAVIGATE Trial Redefines Standards
The NAVIGATE Phase III trial marks the first time MRD testing directly determines when high-risk breast cancer patients start therapy, shifting MRD from experimental tool to a decision-making linchpin in large-scale registrational studies.
October 2026 looked like an inflection point because Natera moved MRD-guided care from promise into pivotal testing. Yahoo Finance reported the headline, “Natera, Genentech Launch 2,000‑Patient NAVIGATE Phase III Trial Using Signatera MRD Test and giredestrant,” and that pairing mattered: a large, late-stage study with a major pharma partner signaled that MRD was no longer being explored only in small validation settings, but was being built directly into registrational-caliber development as a tool for deciding when treatment should begin.
The design of AFT-70 NAVIGATE made that shift concrete. AFT said Boston-based Alliance Foundation Trials and Austin, Texas-based Natera “have launched AFT-70 NAVIGATE, a Phase III trial” that will “enrol more than 2,000 patients… at approximately 200 sites across the US and internationally,” testing whether patients with no detectable MRD can safely defer therapy; critically, “In the investigational arm, a CDK4/6 inhibitor will be added only if longitudinal monitoring with Natera’s Signatera Genome test detects MRD,” showing MRD status functioning as the treatment trigger itself.
MRD Evidence Drives Clinical Impact
A surge of outcome-linked studies across multiple cancers is cementing MRD’s role as a real-time indicator for recurrence risk and treatment response, enabling earlier, more tailored interventions based on molecular status.
Adoption is broadening because MRD is no longer just prognostic in theory; it is increasingly showing that molecular status separates patients into meaningfully different recurrence-risk groups early enough to change care. Investing.com highlighted this in the headline “Myriad's Precise MRD Detects Colorectal, Pancreatic Recurrence Up to Four Months Early, Shows ESMO Data,” while OncoDaily described ctDNA surveillance in colorectal cancer as a tool that can identify patients who may benefit from treatment intensification and those for whom de-escalation may be appropriate, with serial results interpreted alongside established postoperative assessments.
What makes that framework adoptable across tumor types is the accumulation of outcome-linked evidence: Natera said its oncology technology appeared in 25 ESMO abstracts, including data in lung, endometrial, breast, colorectal and gastroesophageal cancers, and OncoDaily noted Natera “participated in major prospective clinical research initiatives, including CIRCULATE, a study involving more than 3,000 patients with colorectal cancer investigating MRD-guided treatment using Signatera.” In the MDT-Bridge lung study, Clarity MRD detected ctDNA in 99% of patients before treatment, and clearance at the second cycle of neoadjuvant therapy had an 83% predictive value for pathologic complete response. Yahoo Finance reported the headline “Natera’s Signatera ctDNA Test Predicts 91% 24‑Month Survival in Bladder Cancer VOLGA Trial at ESMO 2026,” while separate ESMO summaries tied ctDNA clearance in lung, negative predictive value in endometrial, and sustained MRD negativity in breast to better outcomes: in high-risk endometrial cancer, roughly one-fifth of patients were Signatera-positive after surgery, and postoperative Signatera status had a 97% negative predictive value for disease-specific events in the pembrolizumab setting; in HER2-positive metastatic breast cancer, 81% of exceptional responders maintained MRD negativity during serial monitoring.
Serial MRD Testing Goes Routine
Signatera’s rapid growth and expanding insurance coverage are transforming MRD monitoring into a standard, recurring part of survivorship care for diverse cancer types, with real-world patients now routinely tracked every few months.
Signatera’s commercial profile now looks like scaled clinical infrastructure, not a pilot. The Earnings Debate said Natera processed “249,000 clinical oncology units in Q1,” up 55% year over year, while Q1 revenue reached $697 million, up 39%; the gap reflected timing of report delivery and revenue recognition, not weak demand, underscoring that unit growth is the cleaner signal. Just as important, Signatera is used for MRD in a sequential pattern—after surgery, then again months later, and again—so each newly added patient becomes a recurring stream of surveillance tests rather than a one-time order.
That repeat-testing engine is now spreading across oncology practice. Steve Chapman said in BigGo Finance that Signatera spans “more than 20 cancer indications” and “processes roughly 300,000 oncology tests per quarter,” with growth “north of 50% year over year,” while Natera has “submitted 15-plus histologies for coverage and received coverage across eight,” with the remainder “expected over the following 12 months”; its first oncology coverage was in colorectal cancer. That extends reimbursable surveillance into more settings. The real-world cadence is visible in survivorship care too: USA TODAY described Chance Osborne, a triple-negative breast cancer survivor, using “Signatera every three months to monitor her health in survivorship” five years after becoming cancer-free.

